Racecadotril-d5 is intended for use as an internal standard for the quantification of racecadotril by GC- or LC-MS. Racecadotril is a prodrug form of the neprilysin (NEP) inhibitor thiorphan. In vivo, racecadotril reduces or prevents castor oil-induced diarrhea without delaying intestinal transit in rats when administered at doses of 80 or 100 mg/kg, respectively. It also decreases the duration of diarrhea and increases body weight gain in a neonatal gnotobiotic pig model of human rotavirus-induced diarrhea. Formulations containing racecadotril have been used in the treatment of acute diarrhea.
Ambroxol-d5 is intended for use as an internal standard for the quantification of ambroxol by GC- or LC-MS. Ambroxol is an expectorant and active metabolite of bromhexine. It decreases short-circuit currents in electrically stimulated isolated canine tracheal epithelial cells when applied submucosally. Ambroxol decreases IL-13-induced production of mucin 5AC (MUC5AC) in primary human airway epithelial cells and inhibits IL-13-induced decreases in the mucociliary transport rate of endogenous particles in the same cells. Ambroxol increases phenol red secretion, a marker of expectorant activity, in mice when administered at doses of 30, 60, or 120 mg/kg. Formulations containing ambroxol have been used in the treatment of acute or chronic respiratory conditions.